Tarsus Pharmaceuticals price to free cash flow TARS

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Oct 23, 2026: 53.4×
5-year median: 71.6×
Against its 5-year history: 5th; percentile: 0 is its lowest day, 100 its highest
5-year range: 50.8× to 120×
Peer median: 27.9×

Tarsus Pharmaceuticals' price to free cash flow is 53.4× as of Oct 23, 2026.

That is below its 5-year median of 71.6×, lower than on 95% of days in the last 5 years.

Over that time it ranged from 50.8× in Aug 2026 to 120× in Apr 2022.

The median for 10 biotech stocks of a similar size is 27.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	53.4×	50.8×	71.1×
2025	n/m a value too high to mean anything
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	72.6×	53.6×	120×
2021	83.2×	83.2×	101×

Against its peers

Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
TARSTarsus Pharmaceuticals	53.4×
ADMAAdma Biologics	20.5×
VCELVericel	35.3×
KRYSKrystal Biotech	35.8×
RGENRepligen	89.2×
MGTXMeiraGTx	84.5×
TECHBIO-TECHNE	43.2×
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
INCYIncyte	12.2×
Peer median	27.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Tarsus Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.